FOLH1 and prostate carcinoma: Prostate-specific membrane antigen (PSMA) is a type II membrane glycoprotein that is overexpressed in prostate cancer and has been deemed the most promising target for prostate cancer imaging and therapy, to date, as highlighted via the FDA approval of [177Lu]Lu-PSMA-617 (41).